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Abstract 
Small interfering RNAs (siRNA) have a broad potential as therapeutic agents to reversibly 
silence any target gene of interest. The clinical application of siRNA requires the use of safe 
and effective delivery systems. In this study, we investigated the use of non-ionic surfactant 
vesicles (NISV) for the delivery of siRNA. Different types of NISV formulations were 
synthesised by microfluidic mixing and then evaluated for their physiochemical properties 
and cytotoxicity. The ability of the NISV to carry and transfect siRNA targeting green 
fluorescent protein (GFP) into A549 that stably express GFP (copGFP-A549) was evaluated. 
Flow cytometry and Western blotting were used to study the GFP expression knockdown and 
significant knockdown was observed as a result of siRNA delivery to the cells by NISV. This 
occurred in particular when using tween 85, which was able to achieve more than 70% GFP 
knockdown. NISV were thus demonstrated to provide a promising and effective platform for 
therapeutic delivery of siRNA.  
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1. Introduction 
The discovery of the RNA interference (RNAi) mechanism by Fire et al. represents one of 
the most significant advances in molecular biology. This mechanism is an endogenous post-
transcriptional gene regulatory process that involves the degradation of messenger RNA 
(mRNA) in a highly sequence-specific manner [1]. Double-stranded (ds) small interfering 
RNA (siRNA), composed of 21-23 base pairs in length, can induce RNAi and interfere with 
the expression of the protein of the target RNA [2]. The RNAi mechanism involves the 
incorporation of the anti-sense strand of the siRNA into the RNA-induced silencing complex 
in the cytoplasm, followed by cleavage of the target mRNA that is complementary to the anti-
sense strand of the siRNA to cause silencing of the gene encoded by that mRNA [3]. 
Following this discovery, a significant body of research has been carried out to investigate 
the application of RNAi for the treatment of human diseases [4, 5]. For therapeutic 
applications, synthetic siRNA can be designed to target overexpressed genes in human 
diseases such as cancer [6]. The potential application of siRNA therapeutics has been 
demonstrated in different types of cancer, including bladder, ovarian, lung, and prostate 
cancers [7-10]. However, the successful application of siRNA-based therapeutics is 
dependent on the efficient delivery of siRNA to target cells [11]. Naked siRNA has a very 
short half-life as a result of rapid degradation and elimination from the blood by nucleases 
[12]. Moreover, the negative charge of siRNA molecules prevents their passive diffusion 
across hydrophobic cellular membranes in addition to creating electrostatic repulsion with 
negatively charged cellular membrane proteins [13]. Due to the poor stability of siRNA in 
physiological fluids and inefficient cellular uptake, effective delivery of therapeutic siRNA 
into the cytoplasm of target cells is one of the main challenges in the development of siRNA-
based treatments [14]. An ideal siRNA delivery system, for clinical application, should 
protect the siRNA from rapid digestion, efficiently deliver the therapeutic siRNA into the 
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target cells, and promote the subsequent release of siRNA from endosome vesicles into the 
cytoplasm, where they can be loaded into the silencing complex for gene silencing. 
Moreover, the delivery system should be biodegradable with low toxicity.  
Non-viral delivery systems such as liposomes, dendrimers, cell-penetration peptides, and 
many others have been investigated for the delivery of siRNA to expand their clinical 
application [15]. Lipid-based nanoparticles such as liposomes are by far the most studied 
drug-delivery system for this purpose. However, due to the limitations of liposomes, such as 
cost and stability, the delivery of siRNA by non-ionic surfactant vesicles (NISV) have been 
investigated as an alternative. NISV are lipid-based nanoparticles, which are composed of 
non-ionic surfactants, cholesterol, and charged lipids. These components self-assemble upon 
hydration into a bilayer structure enclosing an aqueous core similar to liposomes [16]. NISV 
are generally superior to liposomes in terms of stability and production costs [17]. Different 
types of surfactant can be used in NISV formulations such as Tweens, Spans, Brijs, and many 
others [18]. NISV have been widely investigated as drug delivery systems due to their 
potential to carry and encapsulate a variety of therapeutic agents. However, the application of 
NISV in the field of gene delivery has not been investigated extensively. In terms of nucleic 
acid delivery, most of the research in the literature use these vesicles for DNA delivery [19, 
20], and there is only a limited number of publications describing their use for siRNA 
delivery [21-23]. 
Previously, stable NISV through microfluidics were formulated [18]. In this study, we have 
synthesised cationic NISV (CN) using microfluidics with different surfactants and 
investigated their potential application for siRNA transfection. The cationic charge on the 
formulated NISV was achieved using the cationic lipid didodecyldimethylammonium 
bromide (DDAB), which not only helps with constructing the NISV bilayer structure, but 
also offers positive charge to both bind siRNA drugs and mediate cellular uptake via 
6 
 
electrostatic adhesion to cellular surfaces that carry a slight negative charge. The prepared 
CN were evaluated for their physical characteristics, cytotoxicity, and transfection efficiency. 
Results were compared against a commercially available transfecting reagent, HiPerFect 
(Qiagen, UK). 
 
2. Materials and Methods  
2.1. Materials 
Monopalmitin glycerol (Monohexadecanoin) (MPG) was purchased from Larodan Fine 
Chemicals AB (Sweden). Cholesterol (Chol); polyoxyethylenesorbitan trioleate (Tween 85); 
DDAB; resazurin powder; Tris base; sodium pyrophosphate (Na4P2O7); sodium dodecyl 
sulphate (SDS); bromophenol blue; glycerol; glycine; sodium chloride (NaCl); bovine serum 
albumin (BSA); ethylenediamine tetra-acetic acid (EDTA); Tween 20; 'XOEHFFR¶V0RGLILHG
Eagles medium (DMEM); L-glutamine; and penicillin±streptomycin were purchased from 
Sigma-Aldrich (UK). Foetal bovine serum (FBS) was purchased from Biosera (UK). Sodium 
pyruvate (100mM) and minimum essential medium non-essential amino acids (MEM NEAA) 
were purchased from Life Technologies (UK). Skimmed milk powder was purchased from 
Premier Foods Ltd (UK). The human non-small cell lung cancer (A549) cell line was 
purchased from the American Type Culture Collection (ATCC®). Human non-small cell 
lung cancer A549 cells that stably express Green Fluorescent Protein (copGFP-A549) were 
purchased from Cell Biolabs, Inc., (UK). Sterile, RNase-free phosphate buffered saline 1M 
and sterile RNase-free water were purchased from LONZA (UK). AllStars AF488-labelled 
Negative Control siRNA and HiPerFect transfecting reagent were purchased from Qiagen 
(UK). The anti-GFP DsiRNA (siGFP) duplex sequence (1), and the non-targeting scrambled 
DsiRNA (2) (Table 1) were synthesised by Integrated DNA Technologies (Belgium). A 
rabbit polyclonal antibody against copGFP was purchased from Evrogen JSC (Russia) and a 
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rabbit polyclonal antibody against glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was 
purchased from Santa Cruz Biotechnology (UK). 
Table 1. Sequences of siGFP (1) and non-targeting scrambled DsiRNA (2). 
siRNA sequence (¶-¶ 
1 
Sense rCrGrCrArUrGrArCrCrArArCrArArGrArUrGrArArGrArGCA 
Antisense rUrGrCrUrCrUrUrCrArUrCrUrUrGrUrUrGrGrUrCrArUrGrCrGrGrC 
2 
Sense rCrGrUrUrArArUrCrGrCrGrUrArUrArArUrArCrGrCrGrUAT 
Antisense rArUrArCrGrCrGrUrArUrUrArUrArCrGrCrGrArUrUrArArCrGrArC 
 
2.2. Formulation of cationic NISV (CN) 
CN were prepared by microfluidics as described previously [18] using a NanoAssemblrTM 
(Benchtop, Precision NanoSystems Inc., Canada). Three different CN formulations (A-C) 
were prepared (Table 2). To prepare the CN, the required lipid components at the desired 
ratios were dissolved in ethanol at a final lipid concentration of 10 mg/ml. The lipid phase 
was then injected into the first inlet and the aqueous buffer (sterile RNase-free water) into the 
second inlet of the microfluidic microchannel using disposable syringes. CN were formulated 
at a total flow rate of 12 ml/min and a volumetric flow rate ratio of 3:1 between the aqueous 
and lipid phase at 50ºC. The resulting CN dispersions collected from the outlet stream were 
immediately diluted with sterile RNase-free water in order to reduce the final ethanol content 
in the preparation to 6.25% (v/v).  
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Table 2. Composition of CN formulations prepared by microfluidic mixing.  
Formulation Lipid components Molar ratio 
A MPG:Chol:DDAB 40:40:20 
B MPG:Chol:DDAB 30:50:20 
C T85:Chol:DDAB 40:40:20 
 
2.3. CN characterisation 
Particle size, polydispersity index (PDI), and zeta potential (ZP) of the CN formulations were 
measured by dynamic light scattering (DLS) using a Zetasizer Nano-ZS (Malvern 
Instruments, UK). The samples were diluted in distilled water at a 1/20 dilution and the 
measurements were taken at 25°C.  
2.4. Stability studies of CN 
CN colloidal systems were tested for their stability over a two month storage at room 
temperature (25°C) in a controlled temperature room. ZAverage, PDI, and ZP were measured 
every week. 
2.5. Cytotoxicity of CN formulations 
A549 cells were grown and maintained in DMEM medium supplemented with 10% (v/v) 
FBS, 1% (v/v) L-glutamine and 1% (v/v) penicillin-streptomycin. To evaluate the toxicity of 
the CN, the cells were seeded into a 96-well plate at a density of 1×104
 
per well in 100µl 
medium and incubated for 24 h at 37 °C, 5 % CO2 and 100 % humidity. After 24 h, the cells 
were treated with different concentrations of CN (9.77-1250 µg/mL) suspended in sterile 
RNase-free water. Dimethyl sulphoxide (DMSO, 10% v/v) was used as a positive kill control 
and untreated cells as the negative control. The plates were incubated for 24 h and then 20 µl 
of resazurin (0.1 mg/ml) was added to each well and incubated for a further 24 h (48h total 
9 
 
incubation of cells with the CN formulations).. The quantity of resorufin produced was 
measured on a SpectraMax M5 plate reader (Molecular Devices, USA) at Ex560/Em590. Cell 
viability of the treated cells was expressed as a percentage of the untreated control cells. 
2.6. Preparation of CN/siRNA nioplexes 
CN/siRNA complexes (termed nioplexes) were prepared as follows: an appropriate volume 
of siRNA (from 10 µM stock) was mixed with the desired CN formulation (from a 625 µg/ml 
stock) with pipetting up and down to ensure optimal mixing. The nioplex samples were 
incubated at room temperature for 30 min to allow the formation of transfection complexes. 
For cellular uptake experiments including flow cytometry and fluorescent microscopy, 
AllStars AF488-labelled Negative Control siRNA (Qiagen, UK) was used to monitor 
transfection efficiency. For experiments that involved the GFP knockdown in copGFP-A549 
cells, siGFP (IDT, Belgium) was used. 
2.7. In vitro cellular uptake 
To study the cellular uptake of nioplexes, A549 cells were seeded in 12-well plates at a 
density of 1 x 105 cHOOVSHUZHOOLQȝ/RI'0(0 medium supplemented with 10% (v/v) 
FBS, 1% (v/v) L-glutamine and 1% (v/v) MEM NEAA (without antibiotics). The following 
day, 100 ȝl of each of the AF488-labelled Negative Control siRNA-cationic nioplexes (as 
described in Section 2.6) were added drop-wise to the cells, with gentle plate swirling to 
ensure uniform distribution of the nioplexes. Transfected cells were incubated for 48 h. The 
quantitative cellular uptake was measured using a fluorescence-activated cell sorter (FACS). 
For this purpose, the media was removed and the cells were trypsinised, centrifuged and re-
suspended in FACS buffer (10% v/v FBS in PBS) and analysed on a FACS Canto flow 
cytometer (BD Biosciences; Oxford, UK). Upon acquisition, the cells were gated using 
forward scatter versus side scatter (FCS vs SSC) to eliminate dead cells and debris. Cells 
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(10,000) were collected for each sample and the data analysed with DB FACS Diva software. 
siRNA alone, CN alone, and untreated cells were used as controls. The final siRNA 
concentration after transfection was 10 nM. For qualitative uptake measurements, cells were 
prepared as described above and the cellular uptake of nioplexes were viewed using a Carl 
Zeiss Axio-Imager Z1 microscope (Zeiss, Germany) under a 20X water immersion lens with 
a numeric aperture of 0.80. Fluorescence was excited using a mercury lamp and emission 
recorded using a fluorescein isothiocyanate (FITC) filter block (485/515-530nm). Analysis of 
images was carried out with AxioVision 4.8 software. 
2.8. Silencing efficiency studies 
2.8.1. copGFP-A549 cells preparation 
For the GFP silencing evaluation, copGFP-A549 cells were seeded in 12-well plates at 1x105 
FHOOVPO LQ  ȝ/ '0(0 PHGLum supplemented with 10% (v/v) FBS, 1% (v/v) L-
glutamine, 1% (v/v) MEM NEAA (without antibiotics) 24 h before transfection at 37oC, 5% 
(v/v) CO2 and 100% humidity.  
2.8.2. Evaluating GFP silencing by FACS 
To confirm the transfection efficiency of the selected CN formulations, cells were treated 
with the desired CN formulation encapsulating various concentrations of siGFP (10-100 nM 
final concentration). Control samples contained cells treated with particles alone (mock 
transfection), siGFP alone, untreated cells, and untreated A549 cells (not producing GFP). 
The transfection efficiency of the CN formulations was compared with use of HiPerFect 
transfection reagent. After transfection, the cells were incubated for 72 h at 37 °C, 5 % CO2 
and 100 % humidity, then trypsinised, centrifuged and re-suspended in FACS buffer. A 
FACS Canto flow cytometer was used to conduct flow cytometry analysis to quantify the % 
of GFP expression, the median fluorescence intensity (MFI), and to assess the efficacy of 
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GFP silencing by siGFP delivered by the CN formulations. For each sample, 10,000 events 
were collected. The data obtained were analysed using FACS Diva software. The MFI of 
GFP was used to calculate the percentage gene silencing using the formula: 

	 ൌ ൬ 		൰  ? ? ? 
 
2.8.3. Western blotting to determine GFP silencing 
To further assess the downregulation of GFP protein expression in copGFP-A549 cells by 
siGFP transfected through CN formulations, cells were treated with various concentrations of 
siGFP (10-100 nM) transfected using each of the CN formulations. HiPerFect was used as a 
positive control. Scrambled negative control siRNA was used at a concentration of 100 nM to 
prove that transfection of small, non-targeting RNA molecules will not elicit an effect on the 
cells. Untreated cells, cells treated with naked siGFP, mock transfection (particles alone 
without siRNA), and cells that did not express GFP were used as controls. The cells were 
incubated for 72 h, then the media was removed and the cells were lysed with 250 µl sample 
buffer. The GFP protein levels of samples after transfection were determined by Western 
blotting, normalised with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) levels as a 
loading control. Twenty five µl of cell lysate was loaded and separated using 10% Mini-
PROTEAN® 7*; precast gels (Bio-Rad Laboratories Limited, UK), subjected to 
electrophoresis and then transferred electrophoretically to a nitrocellulose membrane (GE 
Healthcare Life Sciences, UK). The membrane was incubated with a rabbit polyclonal 
antibody against copGFP or GAPDH at 4°C overnight followed by a secondary antibody 
anti-rabbit IgG monoclonal antibody and then visualised by a standard enhanced 
chemiluminescence (ECL) (Thermofisher scientific, UK). Semi-quantification of the bands 
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was performed by densitometry using ImageJ public domain software from the National 
Institutes of Health (http://rsb.info.nih.gov/ij/). 
2.9. Statistical analysis 
All experiments were performed in triplicate and one-way analysis of variance (ANOVA) 
ZDVXVHG WR DVVHVV VWDWLVWLFDO VLJQLILFDQFH7XNH\¶VPXOWLSOHFRPSDULVRQ WHVW DQG W-test was 
performed for paired comparisons. The statistical analysis was performed using Minitab 
software version 17. A value of p<0.05 was considered to be statistically significant. 
 
3. Results 
3.1. Physiochemical characterisation of CN 
CN prepared by microfluidics were assessed for their size, PDI, and ZP (Table 3). All the 
prepared formulations were small in size < 60 nm and had low particle size distribution as 
indicated by their PDI values (<0.2). As a result of using the cationic lipid DDAB, all the 
prepared formulations carried an overall positive ZP value.  
Table 3. Comparison of particle characteristics of different CN formulations prepared 
by microfluidic mixing in terms of size, PDI and ZP. n=3 ± SD 
Formulation Size (nm) PDI ZP (mV) 
A 46.30 ± 0.18 0.10 ± 0.02 49.72 ± 2.80 
B 49.39 ± 0.56 0.17 ± 0.04 51.48 ± 2.99 
C 59.16 ± 1.88 0.19 ± 0.09 47.45 ± 2.43 
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3.2. The effects of the lipid composition on overall stability of CN 
CN colloidal systems stability was monitored over two months at room temperature in terms 
of changes to ZAverage over time. All the CN formulations, A-C, were stable with no 
significant (p>0.05) change in their particles size (Figure 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3. Cytotoxicity of CN on the A549 cell line 
Toxicity of the CN formulations was assessed on A549 cells to quantify cell viability (Figure 
2). The cytotoxicity increased as a function of CN concentration. For all formulations, 
concentrations equal or below 78.13 µg/ml were well tolerated by cells, with 100% cells 
viability. CN concentration above 312.5 µg/ml induce significant (p<0.05) cytotoxicity. As a 
result, all the transfection experiments were carried out at CN concentrations less or equal to 
78.13 µg/ml as a final concentration after transfection to avoid confounding vehicle related 
cytotoxicity with the gene silencing activity of siRNA. 
Figure 1. Stability of CN formulations A-C over two months at 
25 °C. The data represents the mean ± SD (n=3).  
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3.4. Uptake of siRNA nioplexes by A549 cells 
To study the cellular uptake of siRNA encapsulated in CN formulations, A549 cells were 
treated with the various nioplexes prepared with AF488-labelled Negative Control siRNA. 
The treated cells were analysed by fluorescence microscopy for qualitative analysis and with 
FACS for quantitative cellular uptake.  
Figure 2. Cytotoxicity of the CN (formulations A-C) on A549 cells and the 
calculated EC50 values. The data represents the mean ± SD (n=3).  
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As can be seen in Figure 3(A), A549 cells did not present any intracellular siRNA signals 
after incubation with naked siRNA as evidenced by the lack of any green fluorescence 
associated with the cells. Cells treated with AF488-labelled Negative Control siRNA 
encapsulated in the three formulations of the CN A-C showed a strong green fluorescence 
signal indicating siRNA uptake by the cells. The positive control transfection reagent, 
HiPerFect, also displayed an uptake of the AF488-labelled Negative Control siRNA. The CN 
formulations alone, without AF488-labelled Negative control siRNA, showed no 
fluorescence (images not shown). These results were confirmed by FACS studies, where the 
fluorescence histogram of the cells incubated with AF488-labelled Negative Control siRNA 
alone was similar to that of the untreated cells. The histograms for the cells treated with 
AF488-labelled Negative Control siRNA encapsulated in formulations A-C and with the 
HiPerFect transfection reagent show a shift in the FITC values compared to the untreated 
cells (Figure 3(B)) confirming cellular uptake. However, the histogram images indicate a 
variation in the degree of the curve shift of the three formulations. To further analyse this 
variation, the percentage cellular uptake for each formulation was measured (Figure 4) and 
found to be for formulations A and B 93.18 ± 2.10 % and 93.15 ± 0.74 %, respectively with 
no significant (p>0.05) difference between them. These percentages were significantly 
(p<0.05) higher than the uptake achieved using HiPerFect (80.08 ± 1.42 %). The percentage 
cellular uptake achieved with formulation C was 73.71 ± 0.14 %, which was significantly (p< 
0.05) lower than formulations A, B, and HiPerFect. However, the uptake achieved with all 
three formulations and HiPerFect were significantly (p<0.05) higher than the siRNA uptake 
when the cells were treated with siRNA alone without any transfection agent. 
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Figure 3 (A) Fluorescent microscopic images (objective lens 20X) and (B) flow 
cytometry histograms of A549 cell uptake when treated with nioplexes made with 
AF488-labelled siRNA. Images are representative of three independent images 
from each sample. The data present means ± standard deviation (n = 3).  
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3.5.  Silencing efficiency studies 
3.5.1. GFP silencing by FACS 
To assess the GFP knockdown by siGFP delivered by the CN formulations, copGFP-A549 
cells were transfected with various concentrations (10-100 nM) of siGFP using formulations 
A-C to investigate the effect of siRNA dose on transfection activity. siGFP concentrations 
greater than 100 nM were not evaluated in order to avoid possible off-target effects. The 
percentage of GFP expression was calculated compared against untreated cells as 100%. As 
can be seen in Figure 5, all formulations were able to bring down the GFP expression with 
different percentages. Formulation A was the least effective in silencing GFP with a 
Figure 4. FACS results for the percentage cellular uptake of siRNA by A549 cells 
when treated with nioplexes encapsulating AF488-labelled siRNA. *Significant 
(p<0.05) difference from cells treated with siRNA alone. The data represents 
means ± SD (n = 3).  
* 
* 
* * 
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minimum value of GFP expression of 65.79 ± 9.16%, achieved using 50 nM siGFP. For 
formulation B, GFP silencing activity increased progressively with siGFP concentration. At 
10 and 25 nM, the percentages of GFP expression were 78.53 ± 11.22 and 82.82 ± 13.12% 
respectively, which was not significantly (p>0.05) different from formulation A at the same 
concentration. However, when the siGFP concentration increased to 50 and 100 nM, the GFP 
expression was brought down to 40.19 ± 11.68 and 49.97 ± 15.05%, respectively, which was 
significantly (p<0.05) higher than formulation A at the same concentrations. A significant 
down-regulation of GFP expression was determined using formulation C in which the GFP 
expression was brought to about 30% compared to untreated cells at all siGFP concentrations. 
This knockdown efficiency using formulation C was significantly (p<0.05) higher than the 
knockdown achieved using formulations A and B. For example, at 100 nM siGFP 
concentrations, the percentage of GFP expression achieved by formulations A-C were 74.58 
± 1.53, 49.97 ± 15.04, and 27.78 ± 16.51%, respectively, indicating a 3 and 2-fold higher 
siRNA transfection efficiency for formulation C compared with formulations A and B, 
respectively. These results for formulation C were almost the same as that for HiPerFect, 
where the percentage of GFP expression was around 35% at all siGFP concentrations used. In 
contrast, naked siGFP and mock transfection using all formulations showed minimal GFP 
down-regulation. 
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3.5.2. GFP silencing measured by Western blotting 
To further confirm the results obtained above, the relative GFP levels of treated cells with 
different siGFP concentrations (10-100 nM) transfected with the three formulations (A-C) 
Figure 5. Gene down-regulation analysis in copGFP-A549 cells after 
transfection with different anti-GFP siRNA (siGFP) concentrations (10-100 
nM) transfected with formulations A-C and HiPerFect. GFP expression was 
quantified by flow cytometry analysis. Values represent the mean ± SD (n=3). 
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was evaluated in vitro in copGFP-A549 cells by Western blotting. Similar to FACS results, 
all three formulations were able to transfect the copGFP-A549 cells and down-regulate the 
GFP expression by siRNA. As can be seen in Figure 6 (A), formulation C was able to induce 
the highest GFP knockdown at all the concentrations used compared with formulations A and 
B. Moreover, mock transfection, naked siGFP, and scrambled negative control siRNA 
transfected via all formulations did not induce any GFP suppression, which indicates the 
effectiveness of the CN formulations and the specificity of the siGFP used. Semi-
quantification of the bands showed that the GFP expression was 18.79 ± 5.54% when the 
cells were transfected with 10 nM siGFP loaded in formulation C, while cells transfected 
with higher siGFP concentrations (25-100 nM) with formulation C had the same GFP 
expression (~ 10%). These results, achieved by formulation C, were comparable with the 
GFP inhibition achieved using HiPerFect where the GFP expression was about 10% at all 
concentrations used (10-100 nM) (Figure 6 (B)). The percentage GFP expression in cells 
treated with 10 nM siGFP using formulation B was 64.83 ± 5.08%, while the GFP expression 
when the cells were transfected with higher concentrations (25-100 nM) was stable (~55%). 
Formulation A results were comparable with those of formulation B where the GFP 
expression was 68.80 ± 6.18% using 10 nM siRNA, while cells transfected with 25 nM 
resulted in GFP expression of 55.19 ± 7.58%. However, higher concentrations of siGFP 
transfected with formulation A did not achieve higher inhibition of GFP expression. 
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Formulation B 
(A) 
Formulation A 
(B) 
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Formulation C 
Hiperfect 
Figure 6. (A) GFP expression determined by Western blotting after transfecting 
copGFP-A549 cells with various concentrations (10 ± 100 nM) of anti-GFP siRNA 
(siGFP) using formulations A-C and HiPerFect. Mock (cells treated with particles 
only without siRNA), naked siGFP (cells treated with 100 nM siGFP alone without 
transfection formulation), scrambled siRNA (cells treated with negative control 
siRNA delivered by the desired formulation at 100 nM concentration), and GFP ±ve 
cells (A549 cells that are not producing GFP). (B) Densitometric analysis of the 
Western blot shown in (A) determined by ImageJ Software. Results represent the 
mean ± SD of three experiments.  
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4. Discussion  
siRNA has significant potential to act as a gene-specific therapeutic agent for the treatment of 
a wide range of diseases [24]. However, the clinical application of siRNA is limited by the 
development of effective delivery systems. NISV are gaining more interest as a drug delivery 
system for various therapeutic agents [18]. Previous work using formulations that combine 
non-ionic surfactants with phospholipids were used for the delivery of oligonucleotides [25], 
and for siRNA [24]; however, these formulations were a combination between liposomes and 
NISV.  
The present work explored the potential of NISV as a delivery system for siRNA. Three 
different formulations were prepared by microfluidics and they were found to be 
monodisperse and small (<60 nm) which is a desirable characteristic for drug delivery 
systems to enhance the accumulation at the tumour site through the enhanced permeability 
and retention effect [26]. The prepared formulations A-C were shown to have good colloidal 
stability over two months at 25°C.  
The cytotoxicity of the prepared formulations on the A549 cell line was measured to make 
sure any gene knock-down was caused by the siRNA used, rather than from any toxic effect 
of the delivery system. At concentrations less than 78.13 µg/ml, all the formulations were 
non-toxic to the cells and this was consistent with what was reported previously for NISV 
using other formulations [18]. All the following experiments that include siRNA transfection 
were carried out at a final concentration at or below this concentration.  
The transfection efficiency of the formulations was evaluated as a measure of cellular uptake 
of siRNA. Cellular uptake analysis is a primary assay that helps to understand part of the 
transfection process and show the efficiency of the formulations to be internalised when they 
are in contact with the target cells. Gene knockdown by siRNA is an indication that the 
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siRNA has been properly delivered by the vector. However, the transfection process 
sometimes involves a low number of cells which might be inadequate for gene therapy. 
Therefore, one of the main objectives of this work was to achieve high percentages of target 
cell transfection with minimal toxic effects.  
To test the effectiveness of formulations A-C in delivering siRNA into the cells and to 
quantify the cellular uptake, AF488-labelled siRNA was encapsulated into each of the three 
formulations and transfected into A549 cells. Fluorescent microscopy and flow cytometry 
were used to assess the cellular uptake. All three formulations were able to deliver the siRNA 
to the cells as indicated by the strong green fluorescent areas on the microscopy images and 
by the shift in the fluorescence histograms in the FACS results, compared to the untreated 
cells. Cellular uptake is influenced by different factors such as particle size, shape, surface 
charge, and chemistry of the nanoparticles [27]. Regarding the effect of particle size on 
nanoparticle cellular uptake, several studies reported that a 40-50 nm diameter is optimal to 
maximise the cellular uptake in certain mammalian cells [28, 29]. A lower degree of cellular 
uptake was noticed for particle sizes above and below this range [30]. In addition, cationic 
nanoparticles are usually taken up by the cells at a higher rate than anionic particles as a 
result of interaction of the positive charge with negatively charged domains on the cell 
membrane [31]. By analysing the characteristics of the CN formulations A-C, all three were 
carried positive charge and were within the desired size range. These favourable 
characteristics resulted in high cellular uptake for all three formulations, as can be seen in 
FACS and fluorescent microscope results. The percentage cellular uptake was similar for 
formulations A and B and lower for formulation C.  Formulation A and B are similar in their 
compositions as both formulations contain the same lipid components in different ratios, 
while formulation C is composed of Tween 85 as a non-ionic surfactant instead of MPG used 
in formulations A and B. Taking into consideration that all three formulations carry almost 
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the same positive charge, this difference in the cellular uptake between the three formulations 
is attributed to their chemical composition. Another explanation for this difference may be 
due to the fact that formulation C is slightly larger in size (~ 60 nm) than formulations A and 
B (both formulations are ~ 50 nm). This takes formulation C out of the 40-50 nm range, 
which is optimal for cellular uptake.  
Following cellular uptake, an effective delivery system must promote endosomal release of 
siRNA into the cytoplasm for gene silencing [32]. To further examine the efficacy of our 
formulations in delivering siRNA into cells for the purpose of gene silencing, a series of gene 
silencing studies on GFP-producing A549 cells (copGFP-A549) to target GFP expression by 
siGFP were carried out. GFP is a protein that exhibits a bright florescence when exposed to 
light in the blue to ultraviolet range and is used as a marker of gene expression and protein 
targeting in intact cells and organisms [33]. CopGFP-A549 is a commercially available A549 
cell line that is modified by the supplier to ensure they endogenously express copGFP. A 
decrease in GFP fluorescence in these cells after transfection indicates endosome release of 
the siGFP into their cytoplasm where the RNAi knockdown mechanism occurs. By 
monitoring any changes in fluorescence intensity of the GFP-producing cells after 
transfection with anti-GFP siRNA, the efficacy of the delivery system can be judged. 
Therefore, we analysed the copGFP-A549 cells by FACS after transfection with various 
concentrations (10-100 nM) of siGFP using formulations A-C, with HiPerFect as a positive 
control. By comparing the fluorescence of the transfected cells with untreated cells, an 
estimation of the transfection efficiency of the three formulations could be made. FACS 
analysis showed that all three formulations were able to downregulate GFP expression to 
varying degrees. Formulation C was able to suppress GFP expression using siGFP by more 
than 70% compared to the untreated cells at all the siRNA concentrations, which was 
comparable with the GFP knockdown achieved using HiPerFect. The GFP knockdown using 
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formulation C was superior to the GFP knockdown achieved by formulations A and B. These 
GFP knockdown results using the CN formulations were higher than the GFP knockdown 
achieved with other delivery systems. For example, Zhu et al. designed multifunctional 
polymeric micelles for siRNA delivery and targeting GFP production in copGFP-A549 cells. 
With their system, the maximum GFP knockdown they achieved was about 55% compared to 
untreated cells after one transfection as shown by FACS [34]. Zhou et al. were able to 
achieve a maximum of 65% of GFP silencing in human breast cancer cells (MDA-MB-231) 
using 100 nM siGFP transfected through their SPANosome vesicles [24].  
To further understand the transfection efficiency of the CN formulations, we analysed the 
transfected cells using Western blotting for more quantitative measurements of the GFP 
expression. Western blot GFP expression results were consistent with the results obtained by 
FACS. All the prepared formulations were able to suppress the GFP expression with 
formulation C being superior to formulations A and B. These results demonstrated that the 
reduction of GFP expression by the CN/siRNA complexes, demonstrated by protein 
quantification by Western blot, support an RNAi-mediated mechanism of gene silencing after 
endosome release of siGFP into the cytoplasm where the RNAi mechanism occurs.  
Together with the cytotoxicity data, these results also suggests that downregulated gene 
expression due to non-specific toxic effects of the formulations used can be excluded, since 
no effect on GFP expression was obvious when the formulations alone (mock) were used as 
controls which confirms that the observed GFP suppression was due to siGFP transfection 
instead of vehicle-related cytotoxicity. 
It has been reported in the literature that the transfection efficiency by lipid-based 
nanoparticles strongly depends on the chemical composition of the lipids used [35, 36]. The 
data above confirms an efficient delivery of bioactive siRNA into the cytosol after cellular 
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uptake and successful release of nanoparticles or siRNA from endosomes or lysosomes can 
be concluded as a result of the GFP knockdown.  Since it was notable that formulation C 
induced higher gene downregulation than formulations A and B using the same siRNA 
concentrations, the variations in the transfection efficiency between the formulations could be 
explained, in part, by the different endosomal escape ability of the lipids used [37]. Although 
formulation C showed the least cellular uptake compared to the other formulations, this 
superiority in GFP knockdown compared to formulations A and B suggests that the presence 
of Tween 85 enhances the endosome escape for formulation C at a higher rate than the MPG 
in formulations A and B.  
From all the non-ionic surfactant types, Tween surfactants are one of the most commonly 
used in the pharmaceutical industry. It includes Tween 20, Tween 60, Tween 80, and Tween 
85 depending on the hydrophobic tail present. An attractive property in the structure of all the 
Tween surfactants is the presence of the hydrophilic polyoxyethylene chain which has been 
shown to possess a functional interaction with nucleic acids and is used as a gene transfer 
helper [38].  Endosome escape is one of the major barriers for efficient gene delivery. Tween 
surfactants are believed to have a fusogenic property similar to 
dioleoylphosphatidylethanolamine (DOPE), which is one of the most commonly used helper 
lipids in liposome formulations to facilitate endosome escape of liposomes and its nucleic 
acids cargo into the cytosol [39, 40]. From all the Tween surfactant types, Tween 85 is shown 
to have the highest efficacy when used with NISV for DNA delivery in which the particles 
formed were proven to have the highest endosome escape compared to NISV prepared with 
other Tween surfactants [38]. For all these reasons, the presence of T85 in formulation C was 
believed to enhance endosome release of the siGFP into the cytosol, where the RNAi 
mechanism occurs, at a higher rate than formulations A and B, which contributes to the 
enhanced silencing efficiency of the GFP expression.  
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To our knowledge, this is the first report on the use of NISV prepared by microfluidics for the 
delivery of siRNA. The surfactant vesicles therefore could prove a superior technology 
platform for therapeutic siRNA delivery. The present work demonstrates that our CN can be 
used to effectively deliver siRNA in vitro. Future work including cellular trafficking and in 
vivo activity evaluation are currently under investigation. 
Conclusions  
Here, for the first time the development of CN prepared by microfluidics for a siRNA 
delivery was reported. The formulations prepared possessed favourable physical 
characteristics and mediated efficient cytosolic delivery of siRNA. From the formulations 
tested, formulation C that was composed of Tween 85 as a non-ionic surfactant, showed 
superiority over the other two formulations, composed with MPG as the surfactant. The 
transfection efficiency of formulation C was shown to be comparable with the cationic 
transfection reagent, HiPerFect. In conclusion, these novel vectors constitute promising 
agents for delivery of siRNA and deserve further investigation.  
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